Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

被引：12

作者：

Kasi, Pashtoon Murtaza ^{[1
]}

Aushev, Vasily N. ^{[2
]}

Ensor, Joe ^{[2
]}

Langer, Nathan ^{[3
]}

Wang, Christopher Gene ^{[4
]}

Cannon, Timothy Lewis ^{[5
]}

Berim, Lyudmyla Derby ^{[6
]}

Feinstein, Trevor ^{[7
]}

Grothey, Axel ^{[8
]}

McCollom, Joseph William ^{[9
]}

Kalmadi, Sujith R. ^{[10
]}

Zakari, Ahmed ^{[11
]}

Dayyani, Farshid ^{[12
]}

Gravenor, Donald ^{[13
]}

Meyer, Janelle Marie ^{[14
]}

Sharif, Saima ^{[15
]}

Jurdi, Adham A. ^{[2
]}

Liu, Minetta C. ^{[2
]}

Aleshin, Alexey ^{[2
]}

Kopetz, Scott ^{[16
]}

机构：

[1] NewYork Presbyterian Hosp, Englander Inst Precis Med, Weill Cornell Med, New York, NY USA

[2] Natera Inc, Austin, TX USA

[3] Virginia Canc Inst QCCA, Richmond, VA USA

[4] Alabama Oncol, Birmingham, AL USA

[5] Inova Schar Canc Inst, Fairfax, VA USA

[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[7] Piedmont Canc Inst, Atlanta, GA USA

[8] West Canc Ctr, Germantown, TN USA

[9] Parkview Canc Inst, Ft Wayne, IN USA

[10] Ironwood Canc & Res Ctr, Chandler, AZ USA

[11] Adventhlth Canc Inst, Orlando, FL USA

[12] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Orange, CA USA

[13] Baptist Canc Ctr, Memphis, TN USA

[14] Oregon Oncol Specialists, Salem, OR USA

[15] Univ Iowa, Iowa City, IA USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

283-237-255; 281-206-4760-6705; 261-376-454; 281-318-9508; 281-318-9493; 261-492-3532-2370-7650-2454; 261-376; 9; 7; 6; 4; 2;

D O I：

10.1200/JCO.2024.42.3_suppl.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9 / 9

页数：1

共 50 条

[21] A multicenter study to evaluate the impact of circulating tumor DNA guided therapy (BESPOKE) in patients with stage II and III colorectal cancer
Kasi, P. M.
Sawyer, S.
Guilford, J.
Munro, M.
Ellers, S.
Hook, N.
Krinshpun, S.
Moshkevich, S.
Billings, P. R.
Aleshin, A.
ANNALS OF ONCOLOGY, 2020, 31 : S459 - S459
[22] Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D.
Starus, A.
Lamik, A.
Sieber, O.
Begbie, S.
Bonaventura, A.
Rai, S.
Karanth, N.
Underhill, C. R.
Nott, L. M.
Van Hazel, G.
Van Hagen, T.
Wong, M.
Saqib, A.
Eastgate, M.
Srivastav, R.
Chia, J.
Toh, H. C.
Jones, F.
Segelov, E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S710 - S710
[23] Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)
Tie, J.
Cohen, J.
Lahouel, K.
Lo, S. N.
Wang, Y.
Wong, R.
Shapiro, J.
Harris, S.
Khattak, A.
Burge, M.
Horvath, L. G.
Karapetis, C. S.
Shannon, J.
Singh, M.
Yip, D.
Papadopoulos, N.
Tomasetti, C.
Kinzler, K.
Vogelstein, B.
Gibbs, P.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S683 - S683
[24] Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)
Musher, Benjamin L.
Melson, Joshua E.
Amato, Gianni
Chan, David
Hill, Marisa
Khan, Iftekhar
Kochuparambil, Samith T.
Lyons, Susan E.
Orsini, James, Jr.
Pedersen, Susanne K.
Robb, Bruce
Saltzman, Joel
Silinsky, Jennifer
Gaur, Snigdha
Tuck, Melissa K.
LaPointe, Lawrence C.
Young, Graeme P.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (12) : 2702 - 2709
[25] Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping
Nakamura, Y.
Kildal, W.
Misumi, T.
Pradhan, M.
Watanabe, J.
Skrede, O-J
Kotani, D.
Raedt, S. D.
Bando, H.
Kalsnes, J.
Taniguchi, H.
Liestol, K.
Takemasa, I.
Hveem, T. S.
Kato, T.
Novelli, M.
Oki, E.
Kerr, D. J.
Yoshino, T.
Kleppe, A.
ANNALS OF ONCOLOGY, 2024, 35 : S457 - S458
[26] Baseline characteristics as predictors of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients.
Watanabe, Akie
Yang, Charlie
Cheung, Winson Y.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Patient factors related to the real-world adoption of 3 months of adjuvant chemotherapy (ACT) in patients with stage III colorectal cancer (CRC)
Krishnan, Tharani
Leung, Emily
Paulo, Joao
Vasconcelos, Solar
Lim, Howard J.
Loree, Jonathan M.
Davies, Janine Marie
Gill, Karamjit
Gill, Sharlene
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant (adj) or post-adj treatment of stage III and highrisk stage II resected colon cancer patients (pts): The ERASE-CRC project by GONO
Conca, V.
Vetere, G.
Moretto, R.
Lonardi, S.
Antoniotti, C.
Germani, M. M.
Pietrantonio, F.
Bittoni, A.
Carullo, M.
Salvatore, L.
Boccaccino, A.
Ronzoni, M.
Ricagno, G.
Toma, I.
Cupini, S.
Latiano, T. P.
Arcangeli, G.
Masi, G.
Fassan, M.
Cremolini, C.
ANNALS OF ONCOLOGY, 2024, 35 : S70 - S70
[29] Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer
Zhu, Ning
Hu, Hanguang
Yuan, Ying
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
[30] Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer
Ning Zhu
Hanguang Hu
Ying Yuan
Signal Transduction and Targeted Therapy, 7

← 1 2 3 4 5 →